|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
gptkb:methotrexate
chemotherapy
|
|
gptkbp:approvalYear
|
1997
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01XC02
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:blackBoxWarning
|
yes
|
|
gptkbp:blackBoxWarningFor
|
gptkb:progressive_multifocal_leukoencephalopathy
hepatitis B reactivation
fatal infusion reactions
severe mucocutaneous reactions
|
|
gptkbp:CASNumber
|
174722-31-7
|
|
gptkbp:contraindication
|
hypersensitivity to rituximab
severe active infections
|
|
gptkbp:developedBy
|
gptkb:Genentech
gptkb:Biogen_Idec
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:genericName
|
gptkb:rituximab
|
|
gptkbp:halfLife
|
18-22 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rituxan
|
|
gptkbp:indication
|
gptkb:granulomatosis_with_polyangiitis
gptkb:non-Hodgkin's_lymphoma
chronic lymphocytic leukemia
rheumatoid arthritis
microscopic polyangiitis
|
|
gptkbp:KEGGID
|
D08602
|
|
gptkbp:legalStatus
|
prescription only
expired (in many regions)
|
|
gptkbp:macromoleculeType
|
gptkb:CD20
|
|
gptkbp:marketedAs
|
gptkb:Biogen
gptkb:Genentech
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
binds CD20 antigen on B lymphocytes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionRequired
|
https://www.gene.com/download/pdf/rituxan_prescribing.pdf
|
|
gptkbp:PubChem_CID
|
none
DB00073
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:progressive_multifocal_leukoencephalopathy
infections
infusion reactions
cytopenias
|
|
gptkbp:tradeNameInEurope
|
gptkb:MabThera
|
|
gptkbp:UNII
|
M4O4MYW7E5
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Genentech
|
|
gptkbp:bfsLayer
|
5
|